STEM Times of Connecticut: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on STEM Times of Connecticut.

Press releases published on October 6, 2026

26 minutes ago

Resolution Therapeutics to present interim Phase I/II EMERALD study data on RTX001 as a late-breaker at AASLD 2026

Indeterminate GlobeNewswire

26 minutes ago

Caseware Verity-Powered Risk Suggestion Agent Launches to Help Auditors Identify Engagement-Specific Risks

Indeterminate GlobeNewswire

an hour ago

RQ Bio Appoints Gavin Koh as Chief Medical Officer and Strengthens Leadership to Advance RQB01

Indeterminate GlobeNewswire

an hour ago

Angelini Ventures and EIB Co-lead $58 Million Series A Financing in Rouge Therapeutics to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia

Indeterminate GlobeNewswire

an hour ago

Rewind Therapeutics Secures Additional Financing to Advance Oral GPR17 Remyelination Program

Indeterminate GlobeNewswire

an hour ago

RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia

Indeterminate GlobeNewswire

an hour ago

One04 Therapeutics to present late-breaking interim Phase 1 results for CPV-104 in C3 glomerulopathy at ASN Kidney Week followed by Virtual KOL Event

Indeterminate GlobeNewswire

2 hours ago

LUBIS EDA Launches FormalOS: Infrastructure for Systematic, Scalable Formal Verification

Indeterminate GlobeNewswire

2 hours ago

LG U+ selects the Digital Vending Machine® from Bango to expand its subscription bundling

Indeterminate GlobeNewswire

2 hours ago

Press Release : Availability of the aide-mémoire for Q3 2026 results

Indeterminate GlobeNewswire

2 hours ago

Communiqué de presse : Mise en ligne du document «Q3 2026 aide-mémoire »

Indeterminate GlobeNewswire

6 hours ago

YSX TECH. CO. LTD to Hold Extraordinary General Meeting of Shareholders

Indeterminate GlobeNewswire

7 hours ago

Blaize Provides Preliminary Third Quarter 2026 Revenue Update and Full-Year Guidance Update

Indeterminate GlobeNewswire

8 hours ago

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

Indeterminate GlobeNewswire